- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02171143
A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
This is a dose-escalation study. Sequential cohorts of subjects will receive increasing doses of ASP2409 or matching placebo.
Subjects in all cohorts will stay confined in the unit for 3 days. All subjects will have scheduled outpatient visits and be followed for a minimum of 90 days.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Alabama
-
Anniston, Alabama, Verenigde Staten, 36027
- Pinnacle Research Group, LLC
-
-
California
-
Costa Mesa, California, Verenigde Staten, 92626
- West Coast Clinical Trials, Llc
-
-
Florida
-
Clearwater, Florida, Verenigde Staten, 33765
- Clinical Research of West Florida, Inc.
-
Edgewater, Florida, Verenigde Staten, 32132
- Riverside Clinical Research
-
-
North Carolina
-
Raleigh, North Carolina, Verenigde Staten, 27612
- Carolina Phase 1 Research
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45255
- Community Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73122
- Lynn Health Science Institute
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Verenigde Staten, 16635
- Altoona Center for Clinical Research
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75231
- Metroplex Clinical Research Center, LLC
-
San Antonio, Texas, Verenigde Staten, 78217
- Texas Arthritis Research Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject weighs at least 50 kg.
- Subject has a body mass index (BMI) of ≤ 35 kg/m2.
- Subject's 12-lead electrocardiogram (ECG) results are normal at Screening and Day -1 or, if abnormal, the abnormality is not clinically significant
Female subject must be either:
Of non-childbearing potential:
- post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
- documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening).
Or, if of childbearing potential:
- must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.
- must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the Treatment and Observation Period, and for ≥ 120 days after final study drug administration.
Acceptable forms include:
- Established use or oral, injected or implanted hormonal methods of contraception.
- Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault cap) with spermicidal foam/gel/film/ cream/suppository.
- Female subject must not be breastfeeding at Screening or during the Treatment and Observation period and for ≥ 120 days after final study drug administration.
- Female subject must not donate ova starting at Screening and throughout the Treatment and Observation period and for ≥ 120 days after final study drug administration.
- Male subject must not donate sperm starting at Screening and throughout the Treatment and Observation period and for at least ≥ 120 days after final study drug administration.
- Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the Treatment and Observation period and for ≥ 120 days after final study drug administration.
- Subject has Rheumatoid Arthritis (RA) that was diagnosed according to the 1987 revised criteria of the American College of Rheumatology (ACR) ≥ 6 months prior to Screening.
- Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class I, II or III at Screening.
Subject MUST be on concomitant methotrexate (MTX):
- for ≥ 3 months prior to study drug infusion, AND
- at a stable dose (10 - 25 mg/week) for ≥ 28 days prior to study drug infusion and throughout the study.
Subjects on the following medications must remain on a stable regimen: non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, hydroxychloroquine (Plaquenil®), sulfasalazine, oral corticosteroids (≤ 10 mg of prednisone, or equivalent, daily) or low dose opioids (≤ 30 mg of oral morphine, or equivalent, daily) for
≥ 28 days prior to Screening and remain so throughout the Treatment and Observation Period. (The start of Plaquenil and sulfasalazine must be ≥ 2 months prior to study drug infusion.)
- Subject is highly likely to comply with the protocol and complete the study.
Exclusion Criteria:
- Subject has an ongoing clinically significant systemic disease such as uncompensated heart failure, uncontrolled diabetes mellitus, severe hepatic failure or severe pulmonary disease.
- Subject has a history of any malignancy except for adequately-treated, non-melanoma skin cancer and adequately-treated in-situ cervical cancer.
- Subject has a history of severe allergic or anaphylactic reactions.
- Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/substance abuse within past 6 months prior to Screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).
- Subject has a positive test for alcohol or drugs of abuse (excluding drugs prescribed to subject) at Screening or Day -1.
- Subject has/had a viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to Day -1.
- Subject has a past history of serious opportunistic infection.
- Subject is known positive for human immunodeficiency virus (HIV) antibody.
- Subject has a positive tuberculosis (TB) skin test or Quantiferon Gold test at Screening.
- Subject has a positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody at Screening.
Subject's laboratory test results at Screening:
- alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), are ˃ 2 times the upper limit of normal, AND/OR
- are outside the normal limits and considered by the Investigator to be clinically significant with regard to the remaining per-protocol laboratory tests.
- Subject received any live or live attenuated vaccine within 30 days prior to study drug infusion.
- Subject received any systemic immunosuppressant agent, other than (MTX) or stable steroid regimen, within 2 months prior to study drug infusion.
- Subject has previously received any antibody or therapeutic biologic product within 56 days or 5 half-lives, whichever is longer, prior to study drug infusion.
- Subject has previously participated in any interventional clinical study or has received an experimental agent within 56 days or 5 half-lives, whichever is longer, prior to study drug infusion.
- Subject is participating in another clinical trial or has participated in another dose group of the current trial.
- Subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on Day -1.
- Subject has taken Orencia® (abatacept), Nulojix® (belatacept) or any other CTLA4-Ig molecule.
- Subject has any other condition which precludes the subject's participation in the trial.
- Subject has a history of prolonged QT syndrome.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: ASP2409 Dose Escalation
|
intravenous (IV)
|
Placebo-vergelijker: Placebo Dose Escalation
|
intravenous (IV)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Pharmacokinetics of ASP2409 concentration: Area under the concentration - time curve from time 0 up to the last quantifiable concentration (AUClast)
Tijdsspanne: Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Pharmacokinetics of ASP2409 concentration: Area under the concentration - time curve from time 0 extrapolated to infinity (AUCinf)
Tijdsspanne: Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Pharmacokinetics of ASP2409 concentration: Maximum concentration (Cmax)
Tijdsspanne: Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Safety assessed by adverse events
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Safety assessed by laboratory tests
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Safety assessed by electrocardiograms (ECGs)
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Safety assessed by physical examinations
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Safety assessed by vital signs
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Safety assessed by anti-ASP2409 antibody formation
Tijdsspanne: Up to 1 year
|
Up to 1 year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Composite of pharmacokinetics of ASP2409 concentration: tmax, t1/2, Vz, Vss, CLtot
Tijdsspanne: Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Time to attain Cmax (tmax), apparent terminal elimination half-life (t1/2), terminal phase volume (Vz), volume of distribution at steady-state (Vss), and total body clearance (CLtot)
|
Days 1-8, Days 15, 22, 29, 43, 60, 90, and 120
|
Pharmacodynamics of ASP2409: CD86 receptor occupancy
Tijdsspanne: Days 1-3, Days 5, 8, 15, 22, 29, 43, 60, and 90
|
Cluster of Differentiation 86 (CD86), a co-stimulatory ligand on lymphocytes
|
Days 1-3, Days 5, 8, 15, 22, 29, 43, 60, and 90
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2409-CL-0104
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Reumatoïde artritis
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend